Evidence map›Paper›PMID 30953800›Full record

ArticleActa biomaterialia2019

72-Hour in vivo evaluation of nitric oxide generating artificial lung gas exchange fibers in sheep.

Angela Lai, Caitlin T Demarest, Chi Chi Do-Nguyen, Rei Ukita, David J Skoog, Neil M Carleton, Kagya A Amoako, Patrick J Montoya, Keith E Cook

Open access · greenAbstract readEvaluation Study
In one paragraph

Article in Acta biomaterialia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Progress towards permanent respiratory support.Current opinion in organ transplantation · 2024
    Review
  4. Article
  5. Bioengineering Progress in Lung Assist Devices.Bioengineering (Basel, Switzerland) · 2021
    Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Angela LaiCarnegie Mellon University, United States. Electronic address: angelala@andrew.cmu.edu.
Caitlin T DemarestCarnegie Mellon University, United States.
Chi Chi Do-NguyenCarnegie Mellon University, United States.
Rei UkitaCarnegie Mellon University, United States.
David J SkoogCarnegie Mellon University, United States.
Neil M CarletonCarnegie Mellon University, United States.
Kagya A AmoakoUniversity of New Haven, United States.
Patrick J MontoyaMedArray, Inc, United States.
Keith E CookCarnegie Mellon University, United States.
Carnegie Mellon University · USCarnegie Mellon University Qatar · QAUniversity of New Haven · US

Funding

Compliant Thoracic Artificial LungsR01HL089043 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COOK, KEITH E · 2009 to 2017
$4.2M
NHLBI NIH HHS R01 HL089043
6 · The paper itself

Abstract

The large, densely packed artificial surface area of artificial lungs results in rapid clotting and device failure. Surface generated nitric oxide (NO) can be used to reduce platelet activation and coagulation on gas exchange fibers, while not inducing patient bleeding due to its short half-life in blood. To generate NO, artificial lungs can be manufactured with PDMS hollow fibers embedded with copper nanoparticles (Cu NP) and supplied with an infusion of the NO donor S-nitroso-N-acetyl-penicillamine (SNAP). The SNAP reacts with Cu NP to generate NO. This study investigates clot formation and gas exchange performance of artificial lungs with either NO-generating Cu-PDMS or standard polymethylpentene (PMP) fibers. One miniature artificial lung (MAL) made with 10 wt% Cu-PDMS hollow fibers and one PMP control MAL were attached to sheep in parallel in a veno-venous extracorporeal membrane oxygenation circuit (n = 8). Blood flow through each device was set at 300 mL/min, and each device received a SNAP infusion of 0.12 μmol/min. The ACT was between 110 and 180 s in all cases. Blood flow resistance was calculated as a measure of clot formation on the fiber bundle. Gas exchange experiments comparing the two groups were conducted every 24 h at blood flow rates of 300 and 600 mL/min. Devices were removed once the resistance reached 3x baseline (failure) or following 72 h. All devices were imaged using scanning electron microscopy (SEM) at the inlet, outlet, and middle of the fiber bundle. The Cu-PDMS NO generating MALs had a significantly smaller increase in resistance compared to the control devices. Resistance rose from 26 ± 8 and 23 ± 5 in the control and Cu-PDMS devices, respectively, to 35 ± 8 mmHg/(mL/min) and 72 ± 23 mmHg/(mL/min) at the end of each experiment. The resistance and SEM imaging of fiber surfaces demonstrate lower clot formation on Cu-PDMS fibers. Although not statistically significant, oxygen transfer for the Cu-PDMS MALs was 13.3% less than the control at 600 mL/min blood flow rate. Future in vivo studies with larger Cu-PDMS devices are needed to define gas exchange capabilities and anticoagulant activity over a long-term study at clinically relevant ACTs. STATEMENT OF SIGNIFICANCE: In artificial lungs, the large, densely-packed blood contacting surface area of the hollow fiber bundle is critical for gas exchange but also creates rapid, surface-generated clot requiring significant anticoagulation. Monitoring of anticoagulation, thrombosis, and resultant complications has kept permanent respiratory support from becoming a clinical reality. In this study, we use a hollow fiber material that generates nitric oxide (NO) to prevent platelet activation at the blood contacting surface. This material is tested in vivo in a miniature artificial lung and compared against the clinical standard. Results indicated significantly reduced clot formation. Surface-focused anticoagulation like this should reduce complication rates and allow for permanent respiratory support by extending the functional lifespan of artificial lungs and can further be applied to other medical devices.

Indexed as

Artificial OrgansLungNitric OxideS-Nitroso-N-AcetylpenicillamineAnimalsCopperDimethylpolysiloxanesMetal NanoparticlesNylonsSheepTime FactorsCopperDimethylpolysiloxanesNitric OxideNylonspoly(dimethylsiloxane)-polyamide copolymerS-Nitroso-N-AcetylpenicillamineAnti-plateletArtificial lungCoagulationNitric oxideOxygenator

Identifiers

PMID30953800
PMCPMC6513705
OpenAlexW2927216435

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.